Taken together, ANXA6 can down-regulates EGFR, which may inhibit its downstream PI3K/AKT and RAS signaling pathways, thereby affecting a variety of tumor-associated phenotypes, as shown in the Fig. 1. The gene discussed is AKT1; the disease is neoplasm.